Optase Dry Eye Intense Drops recalled over sterility concerns
- Recall date
- April 20, 2026
- Source
- U.S. Food & Drug Administration (FDA) — enforcement report
- Official notice title
- SCOPE HEALTH recalls Optase Dry Eye Intense Drops (Glycerin 0.2%), packaged in 0.33 fl oz, Sterile, Manufactured for Scope Health Inc., 79 M…
- Recall number
- D-0499-2026
- FDA classification
- Class II
- Brand / firm
- SCOPE HEALTH
- Sold / distributed
- Nationwide within the United States
Why it was recalled
Lack of Assurance of Sterility
Class II means using this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.
What was recalled
Optase Dry Eye Intense Drops (Glycerin 0.2%), packaged in 0.33 fl oz, Sterile, Manufactured for Scope Health Inc., 79 Madison Ave., 8th Floor, New York, NY 10016, USA, NDC 72972-002-01.
Get recall alerts
Free email alert whenever SCOPE HEALTH has a new recall — straight from official government data. Unsubscribe anytime.
More recalls from: SCOPE HEALTH